California's top court refused to hold Gilead liable for delaying a safer HIV drug to protect its franchise – a win for ...

Now that we are trying to complete and devise some efforts about how to follow those requirements, it's sometimes being ...

But if the mandatory Most Favored Nation payment model was always meant primarily as a stick to coerce manufacturers into ...

The FDA selected three more technologies for its READI-Home Innovation Challenge, including home blood collection from Becton ...

CoreCare CEO and longevity medicine doctor Hillary Lin said that the evidence backing testing for hypertension and diabetes, ...

Amid ongoing geopolitical complexities and “profound transformations” affecting the pharmaceutical industry, French ...

The Vaccines and Related Biological Products Advisory Committee recommended the same influenza A and B strains found in the ...

The company said it plans to file for approval of the azacitidine/cedazuridine combination pill in myelodysplastic syndromes ...

Orifarm has today unveiled a five-year plan that will see it push into new markets across Europe, with a “significant ...

IL-4 and TSLP with Pfizer’s trispecific antibody, which the firm has moved into Phase III studies in two indications, ...

Draft guidance “talks about things that'll make your life easier and our lives easier,” says CDER Manufacturing Quality ...

With new Phase II atopic dermatitis data for the IL-13 blocker, AbbVie plans to compete with Dupixent and Ebglyss in ...